The newest name in veterinary medicine says it will draw on 60 years of experience to become the most valued company to vets and animal health customers.

The newest name in veterinary medicine says it will draw on 60 years of experience to become the most valued company to vets and animal health customers.

Zoetis Europe, Africa and Middle EastZoetis, formerly the animal health business unit of pharmaceutical giant Pfizer, has relaunched. Its worldwide revenue in 2011 was US$4.23 billion, making it the global leader in the animal health industry. It is number two in the UK market.

Zoetis said it planned to work closely with veterinary practices and other animal health customers to help grow their businesses, and was committed to research and development into new molecules and products for the eight species areas it covers.

Details of the standalone company’s plans and aspirations were revealed at a two-day event in Chantilly, near Paris, attended by European animal health journalists. Senior personnel serving the Europe, Africa and Middle East region said they were committed to being “the most valued company by animal health customers around the world”.

Zoetis’ portfolio includes vaccines, parasiticides, anti-infectives, medicinal feed additives and complementary pharmaceutical products – enhanced, it said, by diagnostic products and other support services.

In the UK, Zoetis said it would look to continuing and building on support services, such as VetSupport+, offered to veterinary customers. John Hanley, vice-president UK, said: “It is more than a name change in terms of the business, but we are also keen to emphasise the things that aren’t changing. There is much we have done in the past we wish to continue, because there were very successful projects. We don’t have to rationalise any product ranges.

“The analogy I share with our own UK team is we have been given the keys to the car and it is now down to us on how we deliver that to customers.”

Mr Hanley added: “Our philosophy is essentially we can only be successful if we help our customers to be successful. The old model is you went out to sell products. We want to put products into programmes and help vets deliver those to their clients.”.

The UK, Europe and wider region will be served by a total staff of 2,600, with four manufacturing sites and three facilities dedicated to research and development of molecules for existing or emerging diseases. In the UK, Zoetis’ offices will continue to be based at Tadworth, Surrey.

Alejandro BernalAlejandro Bernal, Zoetis executive vice-president and area president of Zoetis’ Europe, Africa and Middle East region, said: “As the largest standalone company in the industry, we are dedicated solely to animal health and focusing on our core business so our customers can grow theirs.

“We are not being born [today]. We have existed as a division of Pfizer Animal Health for 60 years, so we bring with us to create Zoetis’ 60 years of experience of discovering, developing and offering to our customers products, services and complementary solutions to solve all the needs the animal health industry has.

“Our vision is to be the most valued company by animal health customers around the world. It is a significant aspiration, but the most important commitment is to learn more and more about our customers’ needs.”

Pfizer announced last year its animal health business, formed in 1952, would become the standalone business Zoetis. An initial public offering was launched on the New York Stock Exchange on February 1.

A total of 66% of Zoetis revenue is from farm animal products and 34% from companion animal treatments. The name Zoetis was derived from zoetic, meaning “pertaining to life”. The firm says it signals its dedication to supporting veterinary surgeons and livestock farmers.

View your activity >

Leave a Reply

Be the First to Comment!

Notify of